Consoli Arturo, Cancelliere Nicole M, Charbonnier Guillaume, Nishi Hidehisa, Vanek Irene, Marotta Thomas R, Spears Julian, Pereira Vitor M
Diagnostic and Interventional Neuroradiology, Hospital Foch Department of Therapeutic and Interventional Neuroradiology, Suresnes, France
RADIS Lab, St Michael's Hospital Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada.
J Neurointerv Surg. 2024 May 2;17(5):487-492. doi: 10.1136/jnis-2024-021458.
Pulsatile tinnitus (PT) can be a disabling clinical condition, which may be caused by a sigmoid/transverse sinus stenosis (STSS). Intracranial venous stenting with off-label carotid or peripheral venous stents has been used successfully to treat this condition. We present the results of a cohort of patients presenting with PT treated with a novel, dedicated, braided stent for the endovascular treatment of STSS.
Twelve patients presenting with PT and associated STSS were treated at our institution (December 2022-June 2023). All clinical and procedural variables were prospectively collected. We used the Tinnitus Function Index (TFI) and the Tinnitus Handicap Inventory (THI) scores to assess the impact of PT on quality of life before and after the treatment (mean follow-up: 10.3 months).
Twelve women (mean age: 44±16.5 years) presenting with PT and STSS were treated. Mean pretreatment TFI/THI scores were 78.8/77. The BosStent was successfully deployed in all patients. We experienced no intraprocedural/postoperative complications. Intra-stent angioplasty was performed in three cases. All patients reported a complete resolution of PT symptoms within 1 month and remained stable and PT-free at the last follow-up (mean posttreatment TFI/THI score: 7.1/5, p<0001).
The BosStent was successfully used in a cohort of patients with PT without any intraprocedural complications. All the patients experienced a complete resolution of PT symptoms after 1 month, which was stable during the follow-up period. Further studies with larger populations will be necessary to investigate the safety and effectiveness of this novel stent for the treatment of PT with STSS.
搏动性耳鸣（PT）可能是一种致残性临床病症，可由乙状窦/横窦狭窄（STSS）引起。使用未按说明书使用的颈动脉或外周静脉支架进行颅内静脉支架置入术已成功用于治疗这种病症。我们展示了一组患有PT并接受新型专用编织支架进行STSS血管内治疗的患者的结果。
我们机构（2022年12月至2023年6月）治疗了12例患有PT及相关STSS的患者。前瞻性收集了所有临床和手术变量。我们使用耳鸣功能指数（TFI）和耳鸣障碍量表（THI）评分来评估治疗前后PT对生活质量的影响（平均随访时间：10.3个月）。
治疗了12名患有PT和STSS的女性（平均年龄：44±16.5岁）。治疗前TFI/THI平均评分分别为78.8/77。所有患者均成功植入BosStent支架。我们未发生术中/术后并发症。3例患者进行了支架内血管成形术。所有患者均报告在1个月内PT症状完全缓解，且在最后一次随访时保持稳定且无PT症状（治疗后TFI/THI平均评分：7.1/5，p<0.001）。
BosStent支架成功用于一组PT患者，无任何术中并发症。所有患者在1个月后PT症状完全缓解，随访期间保持稳定。需要进行更大规模人群的进一步研究，以调查这种新型支架治疗伴有STSS的PT的安全性和有效性。
